← back to search

İftihar Köksal

Karadeniz Technical University · CH
Area of research
Hepatology · Infectious Diseases
Research interest
Research interests include Hepatitis C virus research, Viral Infections and Vectors, Hepatitis B Virus Studies, and Nosocomial Infections in ICU.
h-index
33
citations
5,438
works
242
NIH funding
primary concept
Medicine
email

Recent publications

Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial
The Lancet Infectious Diseases 2024cited by 49position: middledoi
Incidence and risk factors for catheter-associated urinary tract infection in 623 intensive care units throughout 37 Asian, African, Eastern European, Latin American, and Middle Eastern nations: A multinational prospective research of INICC
Infection Control and Hospital Epidemiology 2024cited by 16position: middledoi
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial
Critical Care 2022cited by 89position: middledoi
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Clinical Infectious Diseases 2019cited by 393position: middledoi
ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
Gastroenterology 2014cited by 368position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

V.P. Stus · Centre for Cancer Biology1 papers (2019–2019) · 1 papers (2014–2014)Péter Ferenci · Medical University of Vienna1 papers (2014–2014)Amanda Paschke · Merck & Co., Inc., Rahway, NJ, USA (United States)1 papers (2019–2019)Jeffrey Enejosa · AbbVie (United States)1 papers (2014–2014)Pietro Andreoné · University of Modena and Reggio Emilia1 papers (2014–2014) · 1 papers (2014–2014) · 1 papers (2019–2019)Helen W. Boucher · University of Alabama at Birmingham1 papers (2019–2019)Robert Tipping · Bristol Royal Infirmary1 papers (2019–2019)Thomas M. File · University of Illinois Chicago1 papers (2019–2019) · 1 papers (2014–2014) · 1 papers (2019–2019)Angela Aggrey · Merck & Co., Inc., Rahway, NJ, USA (United States)1 papers (2019–2019)Keith S. Kaye · Rutgers, The State University of New Jersey1 papers (2019–2019)Massimo Colombo · Medizinische Hochschule Hannover1 papers (2014–2014)Barry Bernstein · AbbVie (United States)1 papers (2014–2014)Thomas Podsadecki · AbbVie (United States)1 papers (2014–2014)O. O. Lyulko · Indiana University – Purdue University Indianapolis1 papers (2019–2019) · 1 papers (2019–2019)